Charles River Laboratories Intl. Inc vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $232.72 (market cap $11.14B), while Vanguard S&P 500 Growth Index Fund ETF trades at $83.07. Which is the better fit depends on your goals.
| CRL | VOOG | |
|---|---|---|
Market Cap | $11.14B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $233.60 | $85.11 |
52-Week Low | $145.57 | $65.32 |
Enterprise Value | $14.00B | — |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
VOOG (Vanguard S&P 500 Growth ETF) trades at $82.02, down 1.55% on the day, with a bullish technical signal from moving averages. The ETF recently completed a 1:6 stock split on April 21, 2026, making shares more accessible. Technical indicators show neutral oscillators but bullish moving average alignment, with support clustered around $82.
The ETF's outlook remains positive given its focus on S&P 500 growth stocks and low 0.07% expense ratio. Key risks include technology sector concentration and market volatility. Recent financial media coverage highlights VOOG's strong long-term performance potential compared to peer growth ETFs.
Trailing returns across standard periods
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →